GLP-1 and Intestinal Diseases

Jenna Elizabeth Hunt; Jens Juul Holst; Palle Bekker Jeppesen; Hannelouise Kissow

doi:10.3390/biomedicines9040383

GLP-1 and Intestinal Diseases

Jenna Elizabeth Hunt, Jens Juul Holst, Palle Bekker Jeppesen, Hannelouise Kissow

Research output: Contribution to journal › Review › peer-review

55 Citations (Scopus)

87 Downloads (Pure)

Abstract

Accumulating evidence implicates glucagon-like peptide-1 (GLP-1) to have, beyond glucose maintenance, a beneficial role in the gastrointestinal tract. Here, we review emerging data investigating GLP-1 as a novel treatment for intestinal diseases, including inflammatory bowel diseases, short-bowel syndrome, intestinal toxicities and coeliac disease. Possible beneficial mechanisms for these diseases include GLP-1′s influence on gastric emptying, its anti-inflammatory properties and its intestinotrophic effect. The current knowledge basis derives from the available GLP-1 agonist treatments in experimental animals and small clinical trials. However, new novel strategies including dual GLP-1/GLP-2 agonists are also in development for the treatment of intestinal diseases.

Original language	English
Article number	383
Journal	Biomedicines
Volume	9
Issue number	4
Number of pages	14
ISSN	2227-9059
DOIs	https://doi.org/10.3390/biomedicines9040383
Publication status	Published - 2021

Access to Document

10.3390/biomedicines9040383Licence: CC BY

GLP-1 and Intestinal DiseasesFinal published version, 263 KBLicence: CC BY

Library access?

Check availability at the Royal Danish Library

Cite this

@article{baa8b4c79a3042b4aecd8b5a616a4903,

title = "GLP-1 and Intestinal Diseases",

abstract = "Accumulating evidence implicates glucagon-like peptide-1 (GLP-1) to have, beyond glucose maintenance, a beneficial role in the gastrointestinal tract. Here, we review emerging data investigating GLP-1 as a novel treatment for intestinal diseases, including inflammatory bowel diseases, short-bowel syndrome, intestinal toxicities and coeliac disease. Possible beneficial mechanisms for these diseases include GLP-1′s influence on gastric emptying, its anti-inflammatory properties and its intestinotrophic effect. The current knowledge basis derives from the available GLP-1 agonist treatments in experimental animals and small clinical trials. However, new novel strategies including dual GLP-1/GLP-2 agonists are also in development for the treatment of intestinal diseases.",

author = "Hunt, {Jenna Elizabeth} and Holst, {Jens Juul} and Jeppesen, {Palle Bekker} and Hannelouise Kissow",

year = "2021",

doi = "10.3390/biomedicines9040383",

language = "English",

volume = "9",

journal = "Biomedicines",

issn = "2227-9059",

publisher = "MDPI AG",

number = "4",

}

TY - JOUR

T1 - GLP-1 and Intestinal Diseases

AU - Hunt, Jenna Elizabeth

AU - Holst, Jens Juul

AU - Jeppesen, Palle Bekker

AU - Kissow, Hannelouise

PY - 2021

Y1 - 2021

N2 - Accumulating evidence implicates glucagon-like peptide-1 (GLP-1) to have, beyond glucose maintenance, a beneficial role in the gastrointestinal tract. Here, we review emerging data investigating GLP-1 as a novel treatment for intestinal diseases, including inflammatory bowel diseases, short-bowel syndrome, intestinal toxicities and coeliac disease. Possible beneficial mechanisms for these diseases include GLP-1′s influence on gastric emptying, its anti-inflammatory properties and its intestinotrophic effect. The current knowledge basis derives from the available GLP-1 agonist treatments in experimental animals and small clinical trials. However, new novel strategies including dual GLP-1/GLP-2 agonists are also in development for the treatment of intestinal diseases.

AB - Accumulating evidence implicates glucagon-like peptide-1 (GLP-1) to have, beyond glucose maintenance, a beneficial role in the gastrointestinal tract. Here, we review emerging data investigating GLP-1 as a novel treatment for intestinal diseases, including inflammatory bowel diseases, short-bowel syndrome, intestinal toxicities and coeliac disease. Possible beneficial mechanisms for these diseases include GLP-1′s influence on gastric emptying, its anti-inflammatory properties and its intestinotrophic effect. The current knowledge basis derives from the available GLP-1 agonist treatments in experimental animals and small clinical trials. However, new novel strategies including dual GLP-1/GLP-2 agonists are also in development for the treatment of intestinal diseases.

U2 - 10.3390/biomedicines9040383

DO - 10.3390/biomedicines9040383

M3 - Review

C2 - 33916501

SN - 2227-9059

VL - 9

JO - Biomedicines

JF - Biomedicines

IS - 4

M1 - 383

ER -